HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Zika virus epidemic in Brazil. I. Fatal disease in adults: Clinical and laboratorial aspects.

AbstractBACKGROUND:
Zika virus (ZIKV) was first detected in Brazil in May 2015 and the country experienced an explosive epidemic. However, recent studies indicate that the introduction of ZIKV occurred in late 2013. Cases of microcephaly and deaths associated with ZIKV infection were identified in Brazil in November, 2015.
OBJECTIVES:
To determine the etiology of three fatal adult cases.
STUDY DESIGN:
Here we report three fatal adult cases of ZIKV disease. ZIKV infection in these patients was confirmed by cells culture and/or real-time reverse transcriptase polymerase chain reaction (RT-qPCR) and by antigen detection using immunohistochemical assay. Samples of brain and other selected organs taken at autopsy from three patients were also analyzed by histopathological and immunohistological examination.
RESULTS:
The first patient, a 36-year-old man with lupus and receiving prednisone therapy, developed a fulminant ZIKV infection. At autopsy, RT-qPCR of blood and tissues was positive for ZIKV RNA, and the virus was cultured from an organ homogenate. The second patient, a previously healthy female, 16 years of age, presented classic symptoms of Zika fever, but later developed severe thrombocytopenia, anemia and hemorrhagic manifestations and died. A blood sample taken on the seventh day of her illness was positive RT-PCR for ZIKV RNA and research in the serum was positive for antinuclear factor fine speckled (1/640), suggesting Evans syndrome (hemolytic anemia an autoimmune disorder with immune thrombocytopenic purpura) secondary to ZIKV infection. The third patient was a 20-year-old woman hospitalized with fever, pneumonia and hemorrhages, who died on 13days after admission. Histopathological changes were observed in all viscera examined. ZIKV antigens were detected by immunohistochemistry in viscera specimens of patients 1 and 3. These three cases demonstrate other potential complications of ZIKV infection, in addition to microcephaly and Guillain-Barre syndrome (GBS), and they suggest that individuals with immune suppression and/or autoimmune disorders may be at higher risk of developing severe disease, if infected with ZIKV.
AuthorsRaimunda S S Azevedo, Marialva T Araujo, Arnaldo J Martins Filho, Consuelo S Oliveira, Bruno T D Nunes, Ana C R Cruz, Ana G P A C Nascimento, Rita C Medeiros, Cezar A M Caldas, Fernando C Araujo, Juarez A S Quaresma, Barbara C B Vasconcelos, Maria G L Queiroz, Elizabeth S Travassos da Rosa, Daniele F Henriques, Eliana V P Silva, Jannifer O Chiang, Lívia C Martins, Daniele B A Medeiros, Juliana A Lima, Márcio R T Nunes, Jedson F Cardoso, Sandro P Silva, Pei-Yong Shi, Robert B Tesh, Sueli G Rodrigues, Pedro F C Vasconcelos
JournalJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology (J Clin Virol) Vol. 85 Pg. 56-64 (12 2016) ISSN: 1873-5967 [Electronic] Netherlands
PMID27835759 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 Elsevier B.V. All rights reserved.
Chemical References
  • Antigens, Viral
  • RNA, Viral
Topics
  • Adolescent
  • Adult
  • Antigens, Viral (analysis)
  • Autopsy
  • Brain (virology)
  • Brazil
  • Fatal Outcome
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • RNA, Viral (blood)
  • Real-Time Polymerase Chain Reaction
  • Virus Cultivation
  • Viscera (virology)
  • Young Adult
  • Zika Virus (isolation & purification)
  • Zika Virus Infection (diagnosis, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: